Plasma levels of MMPs and TIMP-1 in urinary bladder cancer patients
DOI:
https://doi.org/10.15419/bmrat.v5i1.407Keywords:
Bladder cancer, MMPs, plasma biomarkers, TIMP-1Abstract
Background: Urinary bladder cancer (UBC) is the ninth most frequently diagnosed cancer worldwide. Early diagnosis and treatment can improve survival of patients. In order to improve the diagnostic accuracy of non-invasive urinary bladder cancer, a large number of tumor markers have been identified and strictly assessed. Some of the best candidates as predictive markers in oncologic diseases belong to the family of matrix metalloproteinases (MMPs). The main focus of investigation in this study was on MMP-1, MMP-2, MMP-3, MMP-8, MMP-9 and tissue inhibitor of metalloproteinase 1 (TIMP-1) as plasma biomarkers in patients with urinary bladder cancer (depending on tumor stage).
Methods: Plasma levels of MMP-9 were significantly higher in all patients with UBC compared to control subjects. The plasma level of MMP-8 in Stage III UBC patients was 1.2 times higher than in control group. The plasma level of MMP-3 was higher in patients with bladder cancer of Stage I, II or III (compared to control subjects). Moreover, high plasma levels of TIMP-1 were observed in patients with UBC stages III and IV.
Results: Overall, the measurements of circulating blood levels of MMP-1 and MMP-2 are progressively dissimilar among the various groups (UBC versus control subjects). Thus, changes in MMP levels may be used for monitoring and/or predicting progression of UBC.
References
Al-Alem, L., & Curry, T. E., Jr. (2015). Ovarian cancer: Involvement of the matrix metalloproteinases. Reproduction (Cambridge, England), 150(2), R55–R64. https://doi.org/10.1530/REP-14-0546 PMID:25918438
Decock, J., Hendrickx, W., Vanleeuw, U., Van Belle, V., Van Huffel, S., Christiaens, M.R., Ye, S. and Paridaens, R. (2008). Plasma MMP1 and MMP8 expression in breast cancer: Protective role of MMP8 against lymph node metastasis. BMC Cancer, 8(1), 77. https://doi.org/10.1186/1471-2407-8-77 PMID:18366705
Decock, J., Thirkettle, S., Wagstaff, L., & Edwards, D. R. (2011). Matrix metalloproteinases: Protective roles in cancer. Journal of Cellular and Molecular Medicine, 15(6), 1254–1265. https://doi.org/10.1111/j.1582-4934.2011.01302.x PMID:21418514
Gong, Y., Chippada-Venkata, U. D., & Oh, W. K. (2014). Roles of matrix metalloproteinases and their natural inhibitors in prostate cancer progression. Cancers (Basel), 6(3), 1298–1327. https://doi.org/10.3390/cancers6031298 PMID:24978435
Holanda, A. O., Oliveira, A. R., Cruz, K. J., Severo, J. S., Morais, J. B., Silva, B. B., & Marreiro, D. D. (2017). Zinc and metalloproteinases 2 and 9: What is their relation with breast cancer? Revista da Associação Médica Brasileira, 63(1), 78–84. https://doi.org/10.1590/1806-9282.63.01.78 PMID:28225881
Hrabec, E., Strek, M., Nowak, D., & Hrabec, Z. (2001). Elevated level of circulating matrix metalloproteinase-9 in patients with lung cancer. Respiratory Medicine, 95(1), 1–4. https://doi.org/10.1053/rmed.2000.0923 PMID:11207010
Hua, H., Li, M., Luo, T., Yin, Y., & Jiang, Y. (2011). Matrix metalloproteinases in tumorigenesis: An evolving paradigm. Cellular and Molecular Life Sciences, 68(23), 3853–3868. https://doi.org/10.1007/s00018-011-0763-x PMID:21744247
Huang, J.-F., Du, W. X., & Chen, J. J. (2016). Elevated expression of matrix metalloproteinase-3 in human osteosarcoma and its association with tumor metastasis. Journal of the Balkan Union of Oncology, 21(1), 235–243. PMID:27061553
Keleg, S., Büchler, P., Ludwig, R., Büchler, M. W., & Friess, H. (2003). Invasion and metastasis in pancreatic cancer. Molecular Cancer, 2(1), 14. https://doi.org/10.1186/1476-4598-2-14 PMID:12605717
Klein, T., & Bischoff, R. (2011). Physiology and pathophysiology of matrix metalloproteases. Amino Acids, 41(2), 271–290. https://doi.org/10.1007/s00726-010-0689-x PMID:20640864
Kostova, E., Slaninka Miceska, M., Labacevski, N., Jakjovski, K., Trojacanec, J., Atanasovska, E., Janevski, V., Selmani, R., Petrushevska, G., & Janevska, V.. Journal of Health Sciences (Sarajevo), 2(3), 169–175. https://doi.org/10.17532/jhsci.2012.35
Liotta, L. A., Tryggvason, K., Garbisa, S., Hart, I., Foltz, C. M., & Shafie, S. (1980). Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature, 284(5751), 67–68. https://doi.org/10.1038/284067a0 PMID:6243750
Martin, T.A., Ye, L., Sanders, A.J., Lane, J. and Jiang, W.G.(2013). Cancer Invasion and Metastasis: Molecular and Cellular Perspective. In R. Jandial (Ed.), Metastatic Cancer: Clinical and Biological Perspectives. Austin, Texas: Landes Bioscience.
Mehner, C., Miller, E., Nassar, A., Bamlet, W. R., Radisky, E. S., & Radisky, D. C. (2015). Tumor cell expression of MMP3 as a prognostic factor for poor survival in pancreatic, pulmonary, and mammary carcinoma. Genes & Cancer, 6(11-12), 480–489. PMID:26807201
Mroczko, B., Groblewska, M., Łukaszewicz-Zajac, M., Bandurski, R., Ke˛dra, B., & Szmitkowski, M. (2009). Pre-treatment serum and plasma levels of matrix metalloproteinase 9 (MMP-9) and tissue inhibitor of matrix metalloproteinases 1 (TIMP-1) in gastric cancer patients. Clinical Chemistry and Laboratory Medicine, 47(9), 1133–1139. https://doi.org/10.1515/CCLM.2009.253 PMID:19728856
Murta-Nascimento, C., Schmitz-Dräger, B. J., Zeegers, M. P., Steineck, G., Kogevinas, M., Real, F. X., & Malats, N. (2007). Epidemiology of urinary bladder cancer: From tumor development to patient’s death. World Journal of Urology, 25(3), 285–295. https://doi.org/10.1007/s00345-007-0168-5 PMID:17530260
Nikkola, J., Vihinen, P., Vuoristo, M. S., Kellokumpu-Lehtinen, P., Kähäri, V. M., & Pyrhönen, S. (2005). High serum levels of matrix metalloproteinase-9 and matrix metalloproteinase-1 are associated with rapid progression in patients with metastatic melanoma. Clinical Cancer Research, 11(14), 5158–5166. https://doi.org/10.1158/1078-0432.CCR-04-2478 PMID:16033831
Page-McCaw, A., Ewald, A. J., & Werb, Z. (2007). Matrix metalloproteinases and the regulation of tissue remodelling. Nature Reviews. Molecular Cell Biology, 8(3), 221–233. https://doi.org/10.1038/nrm2125 PMID:17318226
Pittayapruek, P., Meephansan, J., Prapapan, O., Komine, M., & Ohtsuki, M. (2016). Role of Matrix Metalloproteinases in Photoaging and Photocarcinogenesis. International Journal of Molecular Sciences, 17(6), 868. https://doi.org/10.3390/ijms17060868 PMID:27271600
Ploeg, M., Aben, K. K., & Kiemeney, L. A. (2009). The present and future burden of urinary bladder cancer in the world. World Journal of Urology, 27(3), 289–293. https://doi.org/10.1007/s00345-009-0383-3 PMID:19219610
Pollard D (2013) Lung cancer biomarker discovery using proteomic techniques. Lung cancer biomarker discovery using proteomic techniques. PhD thesis, Dublin City University./ Damian Pollard, B.Sc. Hons Lung Cancer Biomarker Discovery using Proteomic Techniques.
Rauvala, M., Puistola, U., & Turpeenniemi-Hujanen, T. (2005). Gelatinases and their tissue inhibitors in ovarian tumors; TIMP-1 is a predictive as well as a prognostic factor. Gynecologic Oncology, 99(3), 656–663. https://doi.org/10.1016/j.ygyno.2005.07.009 PMID:16112717
Rodriguez Faba O, Palou-Redorta J, Fernández-Gómez JM, Algaba F, Eiró N, Villavicencio H, Vizoso FJ (2012) Matrix metalloproteinases and bladder cancer: what is new? [online] ISRN Uro PMID: 22852097
Rose BJ, Kooyman DL (2016). A tale of two joints: the role of matrix metalloproteases in cartilage biology. [online] Dis Markers. PMID: 27478294
Roy, R., Yang, J., & Moses, M. A. (2009). Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer. Journal of Clinical Oncology, 27(31), 5287–5297. https://doi.org/10.1200/JCO.2009.23.5556 PMID:19738110
Ruokolainen, H., Pääkkö, P., & Turpeenniemi-Hujanen, T. (2005). Tissue inhibitor of matrix metalloproteinase-1 is prognostic in head and neck squamous cell carcinoma: Comparison of the circulating and tissue immunoreactive protein. Clinical Cancer Research, 11(9), 3257–3264. https://doi.org/10.1158/1078-0432.CCR-04-2277 PMID:15867221
Shirodkar, S. P., & Lokeshwar, V. B. (2009). Potential new urinary markers in the early detection of bladder cancer. Current Opinion in Urology, 19(5), 488–493. https://doi.org/10.1097/MOU.0b013e32832eb3a0 PMID:19584734
Sunami, E., Tsuno, N., Osada, T., Saito, S., Kitayama, J., Tomozawa, S., Tsuruo, T., Shibata, Y., Muto, T. and Nagawa, H.(2000). MMP-1 is a prognostic marker for hematogenous metastasis of colorectal cancer. The Oncologist, 5(2), 108–114. https://doi.org/10.1634/theoncologist.5-2-108 PMID:10794801
Stivarou, T., & Patsavoudi, E. (2015). Extracellular molecules involved in cancer cell invasion. Cancers (Basel), 7(1), 238–265. https://doi.org/10.3390/cancers7010238 PMID:25629807
Vasala, K., Kuvaja, P., & Turpeenniemi-Hujanen, T. (2008). Low circulating levels of ProMMP-2 are associated with adverse prognosis in bladder cancer. Tumour Biology, 29(5), 279–286. https://doi.org/10.1159/000156705 PMID:18802398
Ylisirniö, S., Höyhtyä, M., & Turpeenniemi-Hujanen, T. (2000). Serum matrix metalloproteinases -2, -9 and tissue inhibitors of metalloproteinases -1, -2 in lung cancer—TIMP-1 as a prognostic marker. Anticancer Research, 20(2B), 1311–1316. PMID:10810441
Decock, J., Hendrickx, W., Vanleeuw, U., Van Belle, V., Van Huffel, S., Christiaens, M.R., Ye, S. and Paridaens, R. (2008). Plasma MMP1 and MMP8 expression in breast cancer: Protective role of MMP8 against lymph node metastasis. BMC Cancer, 8(1), 77. https://doi.org/10.1186/1471-2407-8-77 PMID:18366705
Decock, J., Thirkettle, S., Wagstaff, L., & Edwards, D. R. (2011). Matrix metalloproteinases: Protective roles in cancer. Journal of Cellular and Molecular Medicine, 15(6), 1254–1265. https://doi.org/10.1111/j.1582-4934.2011.01302.x PMID:21418514
Gong, Y., Chippada-Venkata, U. D., & Oh, W. K. (2014). Roles of matrix metalloproteinases and their natural inhibitors in prostate cancer progression. Cancers (Basel), 6(3), 1298–1327. https://doi.org/10.3390/cancers6031298 PMID:24978435
Holanda, A. O., Oliveira, A. R., Cruz, K. J., Severo, J. S., Morais, J. B., Silva, B. B., & Marreiro, D. D. (2017). Zinc and metalloproteinases 2 and 9: What is their relation with breast cancer? Revista da Associação Médica Brasileira, 63(1), 78–84. https://doi.org/10.1590/1806-9282.63.01.78 PMID:28225881
Hrabec, E., Strek, M., Nowak, D., & Hrabec, Z. (2001). Elevated level of circulating matrix metalloproteinase-9 in patients with lung cancer. Respiratory Medicine, 95(1), 1–4. https://doi.org/10.1053/rmed.2000.0923 PMID:11207010
Hua, H., Li, M., Luo, T., Yin, Y., & Jiang, Y. (2011). Matrix metalloproteinases in tumorigenesis: An evolving paradigm. Cellular and Molecular Life Sciences, 68(23), 3853–3868. https://doi.org/10.1007/s00018-011-0763-x PMID:21744247
Huang, J.-F., Du, W. X., & Chen, J. J. (2016). Elevated expression of matrix metalloproteinase-3 in human osteosarcoma and its association with tumor metastasis. Journal of the Balkan Union of Oncology, 21(1), 235–243. PMID:27061553
Keleg, S., Büchler, P., Ludwig, R., Büchler, M. W., & Friess, H. (2003). Invasion and metastasis in pancreatic cancer. Molecular Cancer, 2(1), 14. https://doi.org/10.1186/1476-4598-2-14 PMID:12605717
Klein, T., & Bischoff, R. (2011). Physiology and pathophysiology of matrix metalloproteases. Amino Acids, 41(2), 271–290. https://doi.org/10.1007/s00726-010-0689-x PMID:20640864
Kostova, E., Slaninka Miceska, M., Labacevski, N., Jakjovski, K., Trojacanec, J., Atanasovska, E., Janevski, V., Selmani, R., Petrushevska, G., & Janevska, V.. Journal of Health Sciences (Sarajevo), 2(3), 169–175. https://doi.org/10.17532/jhsci.2012.35
Liotta, L. A., Tryggvason, K., Garbisa, S., Hart, I., Foltz, C. M., & Shafie, S. (1980). Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature, 284(5751), 67–68. https://doi.org/10.1038/284067a0 PMID:6243750
Martin, T.A., Ye, L., Sanders, A.J., Lane, J. and Jiang, W.G.(2013). Cancer Invasion and Metastasis: Molecular and Cellular Perspective. In R. Jandial (Ed.), Metastatic Cancer: Clinical and Biological Perspectives. Austin, Texas: Landes Bioscience.
Mehner, C., Miller, E., Nassar, A., Bamlet, W. R., Radisky, E. S., & Radisky, D. C. (2015). Tumor cell expression of MMP3 as a prognostic factor for poor survival in pancreatic, pulmonary, and mammary carcinoma. Genes & Cancer, 6(11-12), 480–489. PMID:26807201
Mroczko, B., Groblewska, M., Łukaszewicz-Zajac, M., Bandurski, R., Ke˛dra, B., & Szmitkowski, M. (2009). Pre-treatment serum and plasma levels of matrix metalloproteinase 9 (MMP-9) and tissue inhibitor of matrix metalloproteinases 1 (TIMP-1) in gastric cancer patients. Clinical Chemistry and Laboratory Medicine, 47(9), 1133–1139. https://doi.org/10.1515/CCLM.2009.253 PMID:19728856
Murta-Nascimento, C., Schmitz-Dräger, B. J., Zeegers, M. P., Steineck, G., Kogevinas, M., Real, F. X., & Malats, N. (2007). Epidemiology of urinary bladder cancer: From tumor development to patient’s death. World Journal of Urology, 25(3), 285–295. https://doi.org/10.1007/s00345-007-0168-5 PMID:17530260
Nikkola, J., Vihinen, P., Vuoristo, M. S., Kellokumpu-Lehtinen, P., Kähäri, V. M., & Pyrhönen, S. (2005). High serum levels of matrix metalloproteinase-9 and matrix metalloproteinase-1 are associated with rapid progression in patients with metastatic melanoma. Clinical Cancer Research, 11(14), 5158–5166. https://doi.org/10.1158/1078-0432.CCR-04-2478 PMID:16033831
Page-McCaw, A., Ewald, A. J., & Werb, Z. (2007). Matrix metalloproteinases and the regulation of tissue remodelling. Nature Reviews. Molecular Cell Biology, 8(3), 221–233. https://doi.org/10.1038/nrm2125 PMID:17318226
Pittayapruek, P., Meephansan, J., Prapapan, O., Komine, M., & Ohtsuki, M. (2016). Role of Matrix Metalloproteinases in Photoaging and Photocarcinogenesis. International Journal of Molecular Sciences, 17(6), 868. https://doi.org/10.3390/ijms17060868 PMID:27271600
Ploeg, M., Aben, K. K., & Kiemeney, L. A. (2009). The present and future burden of urinary bladder cancer in the world. World Journal of Urology, 27(3), 289–293. https://doi.org/10.1007/s00345-009-0383-3 PMID:19219610
Pollard D (2013) Lung cancer biomarker discovery using proteomic techniques. Lung cancer biomarker discovery using proteomic techniques. PhD thesis, Dublin City University./ Damian Pollard, B.Sc. Hons Lung Cancer Biomarker Discovery using Proteomic Techniques.
Rauvala, M., Puistola, U., & Turpeenniemi-Hujanen, T. (2005). Gelatinases and their tissue inhibitors in ovarian tumors; TIMP-1 is a predictive as well as a prognostic factor. Gynecologic Oncology, 99(3), 656–663. https://doi.org/10.1016/j.ygyno.2005.07.009 PMID:16112717
Rodriguez Faba O, Palou-Redorta J, Fernández-Gómez JM, Algaba F, Eiró N, Villavicencio H, Vizoso FJ (2012) Matrix metalloproteinases and bladder cancer: what is new? [online] ISRN Uro PMID: 22852097
Rose BJ, Kooyman DL (2016). A tale of two joints: the role of matrix metalloproteases in cartilage biology. [online] Dis Markers. PMID: 27478294
Roy, R., Yang, J., & Moses, M. A. (2009). Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer. Journal of Clinical Oncology, 27(31), 5287–5297. https://doi.org/10.1200/JCO.2009.23.5556 PMID:19738110
Ruokolainen, H., Pääkkö, P., & Turpeenniemi-Hujanen, T. (2005). Tissue inhibitor of matrix metalloproteinase-1 is prognostic in head and neck squamous cell carcinoma: Comparison of the circulating and tissue immunoreactive protein. Clinical Cancer Research, 11(9), 3257–3264. https://doi.org/10.1158/1078-0432.CCR-04-2277 PMID:15867221
Shirodkar, S. P., & Lokeshwar, V. B. (2009). Potential new urinary markers in the early detection of bladder cancer. Current Opinion in Urology, 19(5), 488–493. https://doi.org/10.1097/MOU.0b013e32832eb3a0 PMID:19584734
Sunami, E., Tsuno, N., Osada, T., Saito, S., Kitayama, J., Tomozawa, S., Tsuruo, T., Shibata, Y., Muto, T. and Nagawa, H.(2000). MMP-1 is a prognostic marker for hematogenous metastasis of colorectal cancer. The Oncologist, 5(2), 108–114. https://doi.org/10.1634/theoncologist.5-2-108 PMID:10794801
Stivarou, T., & Patsavoudi, E. (2015). Extracellular molecules involved in cancer cell invasion. Cancers (Basel), 7(1), 238–265. https://doi.org/10.3390/cancers7010238 PMID:25629807
Vasala, K., Kuvaja, P., & Turpeenniemi-Hujanen, T. (2008). Low circulating levels of ProMMP-2 are associated with adverse prognosis in bladder cancer. Tumour Biology, 29(5), 279–286. https://doi.org/10.1159/000156705 PMID:18802398
Ylisirniö, S., Höyhtyä, M., & Turpeenniemi-Hujanen, T. (2000). Serum matrix metalloproteinases -2, -9 and tissue inhibitors of metalloproteinases -1, -2 in lung cancer—TIMP-1 as a prognostic marker. Anticancer Research, 20(2B), 1311–1316. PMID:10810441
Downloads
Published
2018-01-23
Issue
Section
Original Research
License
Copyright The Author(s) 2017. This article is published with open access by BioMedPress. This article is distributed under the terms of the Creative Commons Attribution License (CC-BY 4.0) which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.
How to Cite
Plasma levels of MMPs and TIMP-1 in urinary bladder cancer patients. (2018). Biomedical Research and Therapy, 5(1), 1931-1940. https://doi.org/10.15419/bmrat.v5i1.407
